Circulating B7-H4 in serum predicts prognosis in patients with hepatocellular carcinoma

Genetics and Molecular Research

Volumn 14, Issue 4, 2015, Pages 13041-13048

  Zhang, S A ^a   Wu, Z X ^a   Zhang, X ^a   Zeng, Z Y ^a   Li, D L ^a  

^a Department of Gastroenterology   (China)

Author keywords

Hepatocellular carcinoma; Prognostic value; Serum B7 H4

Indexed keywords

ALPHA FETOPROTEIN; V SET DOMAIN CONTAINING T CELL ACTIVATION INHIBITOR 1; VTCN1 PROTEIN, HUMAN;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OVERALL SURVIVAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; SURVIVAL RATE; BLOOD; LIVER TUMOR; PATHOLOGY; PROGNOSIS;

CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; V-SET DOMAIN-CONTAINING T-CELL ACTIVATION INHIBITOR 1;

EID: 84944753847     PISSN: None     EISSN: 16765680     Source Type: Journal    
DOI: 10.4238/2015.October.21.25     Document Type: Article

References (24)

1. Altekruse SF, McGlynn KA and Reichman ME (2009). Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J. Clin. Oncol. 27: 1485-1491.
2. Choi IH, Zhu G, Sica GL, Strome SE, et al. (2003). Genomic organization and expression analysis of B7-H4, an immune inhibitory molecule of the B7 family. J. Immunol. 171: 4650-4654.
3. Duan F and Lam MG (2013). Delivery approaches of gene therapy in hepatocellular carcinoma. Anticancer Res. 33: 4711-4718.
4. Krambeck AE, Thompson RH, Dong H, Lohse CM, et al. (2006). B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. Proc. Natl. Acad. Sci. USA. 103: 10391-10396.
5. Leung J and Suh WK (2013). Host B7-H4 regulates antitumor T cell responses through inhibition of myeloid-derived suppressor cells in a 4T1 tumor transplantation model. J. Immunol. 190: 6651-6661.
6. Liu W, Shibata K, Koya Y, Kajiyama H, et al. (2014). B7-H4 overexpression correlates with a poor prognosis for cervical cancer patients. Mol. Clin. Oncol. 2: 219-225.
7. Liu WH, Chen YY, Zhu SX, Li YN, et al. (2014). B7-H4 expression in bladder urothelial carcinoma and immune escape mechanisms. Oncol. Lett. 8: 2527-2534.
8. Luo RH, Zhao ZX, Zhou XY, Gao ZL, et al. (2005). Risk factors for primary liver carcinoma in Chinese population. World J. Gastroenterol. 11: 4431-4434.
9. Oikonomopoulou K, Li L, Zheng Y, Simon I, et al. (2008). Prediction of ovarian cancer prognosis and response to chemotherapy by a serum-based multiparametric biomarker panel. Br. J. Cancer 99: 1103-1113.
10. Qian Y, Shen L, Cheng L, Wu Z, et al. (2011). B7-H4 expression in various tumors determined using a novel developed monoclonal antibody. Clin. Exp. Med. 11: 163-170.
11. Rahbar R, Lin A, Ghazarian M, Yau HL, et al. (2015). B7-H4 expression by nonhematopoietic cells in the tumor microenvironment promotes antitumor immunity. Cancer Immunol. Res. 3: 184-195.
12. Shi H, Ji M, Wu J, Zhou Q, et al. (2014). Serum B7-H4 expression is a significant prognostic indicator for patients with gastric cancer. World J. Surg. Oncol. 12: 188.
13. Simon I, Zhuo S, Corral L, Diamandis EP, et al. (2006). B7-H4 is a novel membrane-bound protein and a candidate serum and tissue biomarker for ovarian cancer. Cancer Res. 66: 1570-1575.
14. Simon I, Liu Y, Krall KL, Urban N, et al. (2007). Evaluation of the novel serum markers B7-H4, Spondin 2, and DcR3 for diagnosis and early detection of ovarian cancer. Gynecol. Oncol. 106: 112-118.
15. Smith JB, Stashwick C and Powell DJ Jr (2014). B7-H4 as a potential target for immunotherapy for gynecologic cancers: a closer look. Gynecol. Oncol. 134: 181-189.
16. Sun Y, Wang Y, Zhao J, Gu M, et al. (2006). B7-H3 and B7-H4 expression in non-small-cell lung cancer. Lung Cancer. 53: 143-151
17. Tazi el M, Essadi I, M’Rabti H, Touyar A, et al. (2011). Systemic treatment and targeted therapy in patients with advanced hepatocellular carcinoma. N. Am J Med. Sci. 3: 167-175.
18. Tringler B, Zhuo S, Pilkington G, Torkko C, et al. (2005). B7-H4 is highly expressed in ductal and lobular breast cancer. Clin. Cancer Res. 11: 1842-1848.
19. Venook AP, Papandreou C, Furuse J and de Guevara LL (2014).The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist 15 (Suppl) 4: 5-13.
20. Wang X, Wang T, Xu M, Xiao M, et al. (2014). B7-H4 overexpression impairs the immune response of T cells in human cervical carcinomas. Hum. Immunol. 75: 1203-1209.
21. Yi KH and Chen L (2009). Fine tuning the immune response through B7-H3 and B7-H4. Immunol. Rev. 229: 145-151.
22. Zhang J, Zhang M, Jiang W, Wang L, et al. (2009). B7-H4 gene polymorphisms are associated with sporadic breast cancer in a Chinese Han population. BMC Cancer 9: 394.
23. Zhao LW, Li C, Zhang RL, Xue HG, et al. (2014). B7-H1 and B7-H4 expression in colorectal carcinoma: correlation with tumor FOXP3(+) regulatory T-cell infiltration. Acta. Histochem. 116: 1163-1168.
24. Zhu J, Chu BF, Yang YP, Zhang SL, et al. (2013). B7-H4 expression is associated with cancer progression and predicts patient survival in human thyroid cancer. Asian Pac. J. Cancer Prev. 14: 3011-3015.